Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
$169.94
-0.1%
$169.61
$116.49
$179.64
$7.99B0.731.31 million shs2.27 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$54.35
+12.0%
$51.70
$22.28
$59.55
$19.26B1.056.13 million shs20.80 million shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
0.00%+0.84%-1.02%-2.79%+42.47%
Moderna, Inc. stock logo
MRNA
Moderna
0.00%+5.66%-6.83%+18.36%+101.75%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
$169.94
-0.1%
$169.61
$116.49
$179.64
$7.99B0.731.31 million shs2.27 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$54.35
+12.0%
$51.70
$22.28
$59.55
$19.26B1.056.13 million shs20.80 million shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
0.00%+0.84%-1.02%-2.79%+42.47%
Moderna, Inc. stock logo
MRNA
Moderna
0.00%+5.66%-6.83%+18.36%+101.75%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
2.74
Moderate Buy$169.94N/A
Moderna, Inc. stock logo
MRNA
Moderna
1.84
Reduce$35.73-34.25% Downside

Current Analyst Ratings Breakdown

Latest MRNA and IBB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/4/2026
Moderna, Inc. stock logo
MRNA
Moderna
Boost Price TargetNeutral$36.00 ➝ $45.00
5/4/2026
Moderna, Inc. stock logo
MRNA
Moderna
Boost Price TargetSector Perform$35.00 ➝ $38.00
5/1/2026
Moderna, Inc. stock logo
MRNA
Moderna
Boost Price TargetNeutral$43.00 ➝ $49.00
5/1/2026
Moderna, Inc. stock logo
MRNA
Moderna
Set Price Target$33.00
4/2/2026
Moderna, Inc. stock logo
MRNA
Moderna
Boost Price TargetEqual Weight$25.00 ➝ $48.00
3/3/2026
Moderna, Inc. stock logo
MRNA
Moderna
Set Price TargetHold$37.00
2/23/2026
Moderna, Inc. stock logo
MRNA
Moderna
Boost Price TargetOverweight$63.00 ➝ $69.00
2/17/2026
Moderna, Inc. stock logo
MRNA
Moderna
Boost Price TargetSector Perform$25.00 ➝ $30.00
2/17/2026
Moderna, Inc. stock logo
MRNA
Moderna
Set Price Target$35.00
2/17/2026
Moderna, Inc. stock logo
MRNA
Moderna
Reiterated RatingMarket Perform$45.00
(Data available from 5/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
N/AN/AN/AN/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
$1.94B11.09N/AN/A$18.67 per share2.91
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
N/AN/AN/AN/AN/AN/AN/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
-$2.82B-$8.15N/AN/AN/A-143.55%-26.64%-19.32%N/A

Latest MRNA and IBB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2026Q1 2026
Moderna, Inc. stock logo
MRNA
Moderna
-$3.02-$3.40-$0.38-$3.40$236.37 million$389.00 million
2/13/2026Q4 2025
Moderna, Inc. stock logo
MRNA
Moderna
-$2.79-$2.11+$0.68-$2.11$611.14 million$678.00 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
$0.390.23%N/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A

Latest MRNA and IBB Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
3/16/2026
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
Quarterly$0.12180.29%3/17/20263/17/20263/20/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
N/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
0.08
2.41
2.35

Institutional Ownership

CompanyInstitutional Ownership
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
62.45%
Moderna, Inc. stock logo
MRNA
Moderna
75.33%

Insider Ownership

CompanyInsider Ownership
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
N/A
Moderna, Inc. stock logo
MRNA
Moderna
10.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
N/A47.00 millionN/AOptionable
Moderna, Inc. stock logo
MRNA
Moderna
4,700396.79 million353.93 millionOptionable

Recent News About These Companies

How Hantavirus Made Moderna a Must-Own Stock Again
Top Biotech Stocks To Follow Now - May 8th
Moderna stock jumps 10% amid hantavirus outbreak concerns

New MarketBeat Followers Over Time

Media Sentiment Over Time

iShares Biotechnology ETF stock logo

iShares Biotechnology ETF NASDAQ:IBB

$169.94 -0.16 (-0.09%)
As of 05/8/2026 04:00 PM Eastern

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ. The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. Due to the use of representative sampling, the Fund may or may not hold all of the securities that are included in the Index. The Fund’s investment advisor is BlackRock Fund Advisors, which is indirectly owned by BlackRock, Inc.

Moderna stock logo

Moderna NASDAQ:MRNA

$54.35 +5.81 (+11.97%)
Closing price 05/8/2026 04:00 PM Eastern
Extended Trading
$56.35 +2.00 (+3.68%)
As of 05/8/2026 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.